Synastol® TC (Terminalia Chebula Fruit Extract): A Multifunctional Ingredient for Well-Aging Products

In a recent study published in the International Journal of Cosmetic Science, Pierre Fabre researchers evaluated the effects of Synastol® TC on Senomorphic Targets.

Terminalia Chebula Fruit Extract (TC) is an all-natural ingredient that is reproducibly manufactured using a standardized and well-defined process. Earlier studies by Sytheon revealed that TC induced multiple skin benefits by altering tissue architecture, enhancing cutaneous circadian rhythm, reversing protein glycation, strengthening barrier formation, and elevating two key hydration biomarkers, including Filaggrin & Aquaporin-9. Clinically, TC provided visible reduction in signs of facial aging and reversed pollution-induced skin damage. TC is globally approved and certified by ECOCERT COSMOS NATURAL.

Aged skin shows structural, cellular, and molecular changes along with accumulation of senescent cells, which cease to proliferate while remaining metabolically active. Senescent cells secrete a range of inflammatory cytokines, chemokines, proteinases, and small extracellular vesicles (EV) containing miRNAs, collectively called the Senescent Associated Secretary Phenotype (SASP). Skin senescent cells accumulate progressively with age and exert direct impacts on skin structure and function.

Pierre Fabre scientists used senescent human dermal fibroblast (HDF) cells to demonstrate the effects of TC in reversing SASP. Briefly, senescence was induced by exposing HDF cells to ionizing radiation followed by 14-days of incubation with or without TC. Senescence was assessed on day 14 regarding cell morphology, β-galactosidase activity, SASP genes and miRNAs contained in EVs to evaluate beneficial effects of TC compared with untreated controls.

Compared with the untreated controls, treatment of senescent cells with TC exhibited statistically significant down-regulation of β-galactosidase activity along with down regulation of genes related to SASP chemokines, cytokines, and the proteolytic mediator MMP-1. Additionally, TC-treated senescent cells exhibited a strong reduction in key miRNAs in secreted EVs.

In conclusion, this work demonstrates that Synastol® TC bestows strong senomorphic properties, which further validates Sytheon’s earlier mechanistic and clinical studies that show how TC affords positive attributes to skin that are not merely superficial but deep and multi-targeted.

The study was also featured on SpecialChem